BNTX:NASDAQ
BioNTech SE - ADR
97,64 $
arrow_upward
+0,76%(+0,74) 1D
98,98 $
arrow_upward
+1,37% (+1,34)todayPre-market
Closed: 5 қаз., 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
96,74 $
High
98,78 $
Low
95,20 $
Mkt. cap
24,53 млрд
Avg. vol.
1,10 млн
Volume
6,13 мың
52-wk high
123,98 $
52-wk low
79,52 $
EPS
-7,55 $
Beta
1,22
Shares outstanding
251,20 млн
No. of employees
8 мың
Open
96,74 $
High
98,78 $
Low
95,20 $
Mkt. cap
24,53 млрд
Avg. vol.
1,10 млн
Volume
6,13 мың
52-wk high
123,98 $
52-wk low
79,52 $
EPS
-7,55 $
Beta
1,22
Shares outstanding
251,20 млн
No. of employees
8 мың
News stories
From web sources and news partners
Yahoo Finance
·
15 сағат бұрын
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
AD HOC NEWS
·
18 сағат бұрын
BioNTech stock draws Moderate Buy consensus at USD 126 target
AD HOC NEWS
·
23 сағат бұрын
BioNTech CEO Offloads 100,000 Shares as Founders' Exit Talks Turn Testy
AD HOC NEWS
·
1 күн бұрын
Berenberg raises target for BioNTech stock from USD 132 to USD 140
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR